MOTS-c: the mitochondrial-derived peptide, explained
What MOTS-c is, why a peptide encoded in the mitochondrial genome is biologically remarkable, its AMPK and metabolic signalling, the nuclear-translocation finding, and the honest state of the human evidence.
Most peptides in a research catalogue are interesting for what they do. MOTS-c is interesting first for where it comes from. It is encoded not in the nuclear genome, like essentially every other human peptide you will handle, but in the mitochondrial genome. That single fact reframes what mitochondria are understood to be, and it is the reason the molecule attracted attention well beyond metabolic research.
What it is
MOTS-c stands for "mitochondrial open reading frame of the twelve S rRNA type-c". It is a 16-amino-acid peptide with a molecular weight of roughly 2,174 g/mol, transcribed from a short open reading frame within the 12S ribosomal RNA region of mitochondrial DNA. It was first described by Lee and colleagues in 2015.
It belongs to a small class known as mitochondrial-derived peptides, or MDPs, whose other members include humanin and the SHLP family. Before this class was characterised, mitochondrial DNA was generally taught as encoding a fixed set of thirteen proteins, all of them components of the respiratory chain. MDPs indicate that the mitochondrial genome also produces short signalling peptides that act outside the organelle.
The mechanistic picture
AMPK and the folate cycle
The most-cited mechanism connects MOTS-c to AMP-activated protein kinase, the enzyme complex that acts as a cellular energy sensor. The proposed route is indirect and worth stating precisely: MOTS-c is reported to interfere with the folate one-carbon cycle, causing accumulation of the purine intermediate AICAR, which is itself a known AMPK activator. So the effect on AMPK is described as downstream of a metabolic perturbation rather than as direct binding.
Retrograde signalling to the nucleus
The finding that generated the most interest came later. Under metabolic stress, MOTS-c has been reported to translocate from the cytoplasm into the nucleus, where it associates with stress-responsive transcription factors and influences nuclear gene expression. This is described as retrograde signalling: information travelling from mitochondrion to nucleus, rather than the more familiar nucleus-to-mitochondrion direction.
If that model holds, MOTS-c is not simply a metabolic effector. It is a candidate messenger in a communication channel between the two genomes a human cell carries. That is the claim doing the heavy lifting in most of the literature, and it is the one to keep an eye on as replication accumulates.
Exercise and circulating levels
Several studies have measured MOTS-c in human plasma and skeletal muscle, reporting changes associated with exercise and with age. This work is largely observational and correlational. It establishes that the peptide is present and that its levels move, which is a different and much weaker statement than establishing what those movements cause.
What has been demonstrated
- Transcription of a functional peptide from a mitochondrial open reading frame.
- AMPK pathway activation in cultured cells, via the folate cycle and AICAR route.
- Improved insulin sensitivity and resistance to diet-induced obesity in mouse models.
- Nuclear translocation under metabolic stress in cell-culture systems.
- Measurable circulating levels in humans that vary with age and exercise.
What has not happened
There are no large controlled human trials. The metabolic results that drive interest in MOTS-c come predominantly from rodent models, and the gap between a mouse metabolic phenotype and a human clinical outcome is the graveyard of a great many promising compounds. MOTS-c is not an approved medicine in any jurisdiction.
There is also an unresolved technical question underneath the field: how efficiently short mitochondrial open reading frames are actually translated in vivo, and at what abundance. Detection methods for peptides this small are demanding, and the answer matters for whether endogenous MOTS-c operates at concentrations comparable to those used experimentally.
Specifications you will see
MOTS-c is typically supplied lyophilised in 5mg or 10mg vials at 98%+ purity. It is a straightforward peptide to handle: reconstitute in bacteriostatic water, keep it cold, and avoid repeated freeze-thaw cycles. See the reconstitution guide and the storage guide for handling, and the MOTS-c reconstitution calculator for working out concentrations.
Bottom line
MOTS-c is one of the more conceptually significant molecules in the research-peptide catalogue, because the class it belongs to changed a textbook assumption about what mitochondrial DNA encodes. The mechanistic work is genuine and the retrograde-signalling finding is a real result rather than marketing. What it does not yet have is the human evidence base that its metabolic framing tends to imply, and that distinction is worth holding onto.
HelixCore stocks MOTS-c at 98%+ purity per source specifications. Every batch is tested for identity and purity and the certificate is published on the product page. UK stock, Royal Mail Tracked 24 dispatch, supplied strictly for in-vitro laboratory research use only.